Cadrenal Therapeutics Inc... (CVKD)
NASDAQ: CVKD
· Real-Time Price · USD
12.60
-0.32 (-2.48%)
At close: Aug 15, 2025, 3:59 PM
12.69
0.71%
After-hours: Aug 15, 2025, 06:19 PM EDT
Cadrenal Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | 2.13K | n/a | n/a | n/a | 2.77K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 401.00 | 5.52K | 1.07K | 407.00 | 470.00 | 597.00 | 597.00 | 597.00 | 597.00 | 190.00 | 760.00 | 506.00 | n/a | n/a |
Gross Profit | -401 | -5.52K | 1.07K | -407 | -470 | -597 | 2.17K | -597 | -597 | -190 | -760 | -506 | n/a | n/a |
Operating Income | -3.73M | -3.93M | -4.28M | -2.46M | -2.47M | -1.76M | -1.26M | -1.14M | -1.03M | -4.2M | -1.08M | -972.79K | -482.35K | -172.06K |
Interest Income | 67K | 82.6K | 91.16K | 52.13K | 73.64K | 92.33K | 119.77K | 106.14K | 23.18K | n/a | n/a | 3.00 | n/a | n/a |
Pretax Income | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.03M | -502.14K | -176.65K |
Net Income | n/a | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.05M | -502.14K | -178.19K |
Selling & General & Admin | 2.66M | 2.25M | 2.74M | 1.67M | 1.21M | 1.13M | 902.11K | 898.05K | 784.62K | 964.73K | 958.83K | 915.9K | 280.11K | 152.66K |
Research & Development | 1.08M | 1.67M | 1.54M | 784.65K | 1.25M | 629.02K | 361.13K | 243.95K | 240.96K | 3.24M | 116.38K | 56.39K | 202.24K | 17.86K |
Other Expenses | 401.00 | n/a | 407.00 | 407.00 | 470.00 | 597.00 | 596.00 | 597.00 | 597.00 | 190.00 | -506 | 506.00 | n/a | n/a |
Operating Expenses | 3.73M | 3.92M | 4.28M | 2.46M | 2.47M | 1.76M | 1.26M | 1.14M | 1.03M | 4.2M | 1.08M | 972.79K | 482.35K | 170.52K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 17.1K | 55.73K | 32.01K | 14.77K | 4.59K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -389.84K | n/a | n/a | n/a |
Cost & Expenses | 3.73M | 3.93M | 4.28M | 2.46M | 2.47M | 1.76M | 1.26M | 1.14M | 1.03M | 4.2M | 1.08M | 972.79K | 482.35K | 170.52K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 3.00 | 3.00 | n/a | n/a | n/a | -22.85K | 21.31K | n/a | 1.54K |
Shares Outstanding (Basic) | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M | 11.63M | 11.63M |
Shares Outstanding (Diluted) | 1.96M | 1.84M | 1.53M | 1.1M | 1.07M | 1.07M | 868.18K | 868.18K | 781.52K | 781.52K | 775.64K | 11.63M | 11.63M | 11.63M |
EPS (Basic) | -1.87 | -2.09 | -2.75 | -2.18 | -2.24 | -1.55 | -1.32 | -1.19 | -1.28 | -6.62 | -6.46 | -0.09 | -0.04 | -0.02 |
EPS (Diluted) | -1.87 | -2.09 | -2.75 | -2.18 | -2.24 | -1.55 | -1.32 | -1.19 | -1.28 | -6.62 | -6.46 | -0.09 | -0.04 | -0.02 |
EBITDA | -3.73M | -3.84M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.16M | -4.95M | -993.6K | -482.35K | -172.06K |
EBIT | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.16M | -4.95M | -994.1K | -487.37K | -172.06K |
Depreciation & Amortization | 401.00 | 5.52K | 407.00 | 406.00 | 470.00 | 597.00 | 597.00 | 597.00 | 597.00 | 190.00 | 760.00 | 506.00 | 86.06K | 1.54K |